Additional Prothrombin Time Codes NCD Request Denied Due To Lack Of Data
This article was originally published in The Gray Sheet
Executive Summary
CMS' issuance of national non-coverage for coding additions to prothrombin time-testing underscores the agency's emphasis that NCD applications should be backed with supporting medical evidence and data
You may also be interested in...
Medicare Clinical Lab Test Final Rule Has Few Changes After 20-Month Wait
CMS opted to retain a 12-month delay period before implementing its final rule on clinical diagnostic laboratory tests, despite comments from several physicians requesting that the national coverage decision (NCD) policies be adopted earlier
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.